<?xml version='1.0' encoding='utf-8'?>
<document id="26928207"><sentence text="Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers."><entity charOffset="11-20" id="DDI-PubMed.26928207.s1.e0" text="quercetin" /><entity charOffset="44-53" id="DDI-PubMed.26928207.s1.e1" text="cefprozil" /><pair ddi="false" e1="DDI-PubMed.26928207.s1.e0" e2="DDI-PubMed.26928207.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26928207.s1.e0" e2="DDI-PubMed.26928207.s1.e1" /></sentence><sentence text="1" /><sentence text=" The primary objective of this study was to evaluate the effects of quercetin on the pharmacokinetics of cefprozil"><entity charOffset="68-77" id="DDI-PubMed.26928207.s3.e0" text="quercetin" /><entity charOffset="105-114" id="DDI-PubMed.26928207.s3.e1" text="cefprozil" /><pair ddi="false" e1="DDI-PubMed.26928207.s3.e0" e2="DDI-PubMed.26928207.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26928207.s3.e0" e2="DDI-PubMed.26928207.s3.e1" /></sentence><sentence text=" The secondary objective was to evaluate the safety of the combined use of cefprozil and quercetin"><entity charOffset="75-84" id="DDI-PubMed.26928207.s4.e0" text="cefprozil" /><entity charOffset="89-98" id="DDI-PubMed.26928207.s4.e1" text="quercetin" /><pair ddi="false" e1="DDI-PubMed.26928207.s4.e0" e2="DDI-PubMed.26928207.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26928207.s4.e0" e2="DDI-PubMed.26928207.s4.e1" /></sentence><sentence text=" 2" /><sentence text=" An open-label, two-period, crossover phase I trial among 24 Han Chinese male subjects was conducted" /><sentence text=" Participants were given 500 mg of quercetin orally once daily for 15 d followed by single dose of cefprozil (500 mg) on day 15"><entity charOffset="35-44" id="DDI-PubMed.26928207.s7.e0" text="quercetin" /><entity charOffset="99-108" id="DDI-PubMed.26928207.s7.e1" text="cefprozil" /><pair ddi="false" e1="DDI-PubMed.26928207.s7.e0" e2="DDI-PubMed.26928207.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26928207.s7.e0" e2="DDI-PubMed.26928207.s7.e1" /></sentence><sentence text=" Serum concentrations of cefprozil were then measured in all participants on day 15"><entity charOffset="25-34" id="DDI-PubMed.26928207.s8.e0" text="cefprozil" /></sentence><sentence text=" A 15-d washout period was then assigned after which a 500 mg dose of cefprozil was administered and measured in the serum on day 36"><entity charOffset="70-79" id="DDI-PubMed.26928207.s9.e0" text="cefprozil" /></sentence><sentence text=" 3" /><sentence text=" All subjects completed the trial, and no serious adverse events were reported" /><sentence text=" We measured mean serum concentrations of cefprozil in the presence and absence of quercetin in all participants"><entity charOffset="42-51" id="DDI-PubMed.26928207.s12.e0" text="cefprozil" /><entity charOffset="83-92" id="DDI-PubMed.26928207.s12.e1" text="quercetin" /><pair ddi="false" e1="DDI-PubMed.26928207.s12.e0" e2="DDI-PubMed.26928207.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26928207.s12.e0" e2="DDI-PubMed.26928207.s12.e1" /></sentence><sentence text=" The maximum serum concentration of cefprozil in the presence of quercetin was 8"><entity charOffset="36-45" id="DDI-PubMed.26928207.s13.e0" text="cefprozil" /><entity charOffset="65-74" id="DDI-PubMed.26928207.s13.e1" text="quercetin" /><pair ddi="false" e1="DDI-PubMed.26928207.s13.e0" e2="DDI-PubMed.26928207.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26928207.s13.e0" e2="DDI-PubMed.26928207.s13.e1" /></sentence><sentence text="18 ug/ml (95% CI: 7" /><sentence text="55-8" /><sentence text="81) versus a maximum cefprozil concentration of 8"><entity charOffset="21-30" id="DDI-PubMed.26928207.s16.e0" text="cefprozil" /></sentence><sentence text="35 ug/ml (95% CI: 7" /><sentence text="51-9" /><sentence text="19) in the absence of quercetin"><entity charOffset="22-31" id="DDI-PubMed.26928207.s19.e0" text="quercetin" /></sentence><sentence text=" We conclude that the concurrent use of quercetin has no substantial effect on serum concentrations of orally administered cefprozil"><entity charOffset="40-49" id="DDI-PubMed.26928207.s20.e0" text="quercetin" /><entity charOffset="123-132" id="DDI-PubMed.26928207.s20.e1" text="cefprozil" /><pair ddi="false" e1="DDI-PubMed.26928207.s20.e0" e2="DDI-PubMed.26928207.s20.e0" /><pair ddi="false" e1="DDI-PubMed.26928207.s20.e0" e2="DDI-PubMed.26928207.s20.e1" /></sentence><sentence text=" 4" /><sentence text=" Co-administration of quercetin showed no statistically significant effects on the pharmacokinetics of cefprozil in healthy Chinese subjects"><entity charOffset="22-31" id="DDI-PubMed.26928207.s22.e0" text="quercetin" /><entity charOffset="103-112" id="DDI-PubMed.26928207.s22.e1" text="cefprozil" /><pair ddi="false" e1="DDI-PubMed.26928207.s22.e0" e2="DDI-PubMed.26928207.s22.e0" /><pair ddi="false" e1="DDI-PubMed.26928207.s22.e0" e2="DDI-PubMed.26928207.s22.e1" /></sentence><sentence text=" " /></document>